Clinuvel Pharmaceuticals Ltd (CLVLF) income statement

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30
Revenue	64	61	58
Cost of Revenue	11	12	11
Gross Profit	53	50	47
Research & Development	12	13	9.99
General & Administrative	7.38	6.68	6.81
Advertising Expenses	3.08	2.83	1.43
Operating Expenses	25	23	19
Operating Income	28	27	29
Interest & Investment Income	7.09	6.12	4.81
Other Non-Operating Income	0.46	-0.14	0.37
Pretax Income	33	33	33
Income Tax Expense	9.54	9.97	9.87
Net Income	23	23	23
EPS (Basic)(per share)	0.46	0.46	0.47
EPS (Diluted)(per share)	0.46	0.46	0.46
Shares Outstanding (Basic, Weighted)(shares)	50	50	50
Shares Outstanding (Diluted, Weighted)(shares)	51	50	51

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: 82.9%
Operating margin: 43.4%
Net margin: 36.0%
Return on equity, FY2026: 13.4%

Financial strength

Current ratio: 14.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 104.2%

Valuation

P/E ratio: 11.0
Price to sales: 3.96
Price to book: 1.35
Dividend yield: –

See a number that looks wrong?